Development and Recent Advancement of SGLT2 Inhibitors for the Treatment Regime of T2DM

  title={Development and Recent Advancement of SGLT2 Inhibitors for the Treatment Regime of T2DM},
  author={S. Pathania and Nishant Kashyap and Virender Singh and R. Shankar and Kapil Kumar and R. Rawal},
Oral hypoglycemics are involved in the current treatment therapy for type II diabetes mellitus. Continuous research on developing an improved class of oral hypoglycemic led to the development of SGLT2 inhibitors. Their unique mechanism of action made them most sought after the class of oral hypoglycemic. Various clinical studies have disclosed that SGLT2 inhibitors are devoid of many side effects compared to other classes of oral hypoglycemics. Discovery of these inhibitors began with the… Expand
4 Citations
SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review.
Sodium-glucose cotransporter-2 inhibitors are a well-tolerated class with no significant adverse effects and are found to be favorable in certain conditions, which may be rudimentary to cardiovascular and renal diseases. Expand
Synthetic strategy and SAR studies of C-glucoside heteroaryls as SGLT2 inhibitor: A review.
A detailed account of synthetic strategies employed for the synthesis, alternate synthetic routes along with Structure Activity Relationship (SAR) studies of well-established as well as newly developed SGLT2 inhibitors are offered. Expand
Syntheses of Asymmetrically Substituted Pyrans of Natural Origin
Apart from pyranoid carbohydrates, which are the most abundant natural products, there are plenty of secondary metabolites, which contain six membered oxygen heterocyclic ring constituents that areExpand


Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents
The history of research on the development of early-generation S GLT2 inhibitors, and recent progress on the discovery of novel candidates for SGLT2 inhibitor from several natural products that are widely used in traditional herbal medicine are introduced. Expand
SGLT-2 inhibitors: the glucosuric antidiabetics
KGA-2727 (pyrazole-O-glucoside) is the first selective SGLT-1 inhibitor undergoing intense preclinical testing, offering a unique target for achieving adequate control of diabetes in adults. Expand
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor
Sotagliflozin has been developed as a dual inhibitor of S GLT1 and SGLT2, with differentiating clinical features that may have clinical implications for the use of sotag liflozin in the treatment of both type 1 and type 2 diabetes. Expand
SGLT-2 inhibitors and their potential in the treatment of diabetes
Clinicians should embrace the addition to the formulary for treating type 2 diabetes, but must also weight the risk–benefit of this new class in deciding which patient types are most likely to benefit from their novel mechanism of action. Expand
SGLT2 inhibition — a novel strategy for diabetes treatment
The role of SGLT2 in glucose homeostasis and the evidence available so far on the therapeutic potential of blocking these transporters in the treatment of diabetes are discussed. Expand
Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
  • J. White
  • Medicine
  • The Annals of pharmacotherapy
  • 2015
The oral antidiabetes agent, empagliflozin, can be used as monotherapy or alongside other glucose-lowering treatments, including insulin, to treat T2DM. Expand
Dapagliflozin efficacy and safety: a perspective review
Dapagliflozin is a new oral agent for type 2 diabetes with short-term efficacy similar to dipeptidyl peptidase 4 inhibitors; its long-term safety and efficacy are unknown. Expand
Chances and risks of SGLT2 inhibitors
  • P. Mayer
  • Medicine
  • Naunyn-Schmiedeberg's Archives of Pharmacology
  • 2011
The work of Tahara et al. (2011) presents original data on the pharmacodynamic effects of a new representative of the S GLT2 inhibitor class, ipragliflozin, which highlights the perspectives and potentials but also potential drawbacks of SGLT2 inhibition. Expand
Inhibitors of type 2 sodium glucose co-transporters--a new strategy for diabetes treatment.
Although this group of medications is still under investigation, their efficacy in the treatment of type 2 diabetes mellitus (T2D) is very promising, with some of these inhibitors currently undergoing clinical trials. Expand
Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
SGLT2 inhibitors have the potential to reverse glucose toxicity, and to improve insulin resistance, blood pressure and lipid profile, and clinicians should carefully prescribe these drugs in light of already reported and/or unexpected side‐effects. Expand